Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Arch Ventures, Versant Ventures Lead $50M Funding In Drug-Hunting Startup
Venture Capital

Arch Ventures, Versant Ventures Lead $50M Funding In Drug-Hunting Startup

by xconomy.com posted 1year ago 259 views
Vividion Therapeutics is launching with $50 million pledged from investment firms Arch Venture Partners and Versant Ventures. Former Celgene president of research and early development Tom Daniel—who, as Xconomy reported previously, left the company over the summer to begin advising biotechs and venture firms—is executive chairman.